Watch the recording
It can be challenging to develop an economic model in rare diseases that optimises HTA and reimbursement outcomes. It can be difficult to fully capture the effects of the disease and the benefits of treatment whilst using sufficiently robust data to minimise uncertainty.
This webinar introduces a new approach in which multiple companies collaborate to develop a core economic model and common data set. An approach that aims to optimise HTA and reimbursement outcomes for all new treatments in a rare disease.
Speakers: Prof. Keith Abrams, Prof. John Brazier, Dr. Jill Carlton, Josie Godfrey, Jamie O’Hara, Dr Mark Larkin, PhD, and Juliet Mumby-Croft
JG ZEBRA CONSULTING LTD, HCD Economics Ltd, University of Leicester, University of York, The University of Sheffield, Vitaccess, Source Health Economics.
#ProjectHERCULES #rarediseases #heor #healtheconomics #evidencebasedmedicine #pharmaceuticalindustry
